香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 570 更新有關 (1)金融服務（2026-2028年）框架協議； (2)總採購（2026-2028年）協議； 及 (3)總供應（2026-2028年）協議之持續關連交易 本公司之財務顧問 獨立董事委員會及獨立股東之獨立財務顧問 金融服務（2026-2028年）框架協議 於2025年11月25日，本公司與國藥財務訂立金融服務（2026-2028年）框架協議，據此， 國藥財務同意自2026年1月1日起至2028年12月31日向本集團提供為期三年的財務服 務。 - 1 - 總採購（2026-2028年）協議 於2025年11月25日，本公司與國藥集團訂立總採購（2026-2028年）協議，據此，本集團 有條件同意自2026年1月1日起至2028年12月31日止期間內採購由中國醫藥集團供應之 該等原 ...

CHINA TRADITIONAL CHINESE MEDICINE HOLDINGS CO. LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 於本公告日期，國藥集團持有1,685,055,642股股份，佔已發行股份總數之約33.46%。 國藥財務由國藥集團、中國生物、國藥中藥、上海現代製藥及國藥控股分別擁有約 52.7750%、31.7705%、5.4545%、5.4545%及4.5455%股權。因此，國藥財務為本公司 關連人士，故根據上市規則第14A章，新金融服務（2025年）框架協議及其項下擬進行 之交易構成本公司之持續關連交易。 - 1 - 本公司已與國藥財務訂立新金融服務（2025年）框架協議，內容涵蓋存款服務、貸款服 務及其他財務服務。就存款服務而言，由於新金融服務（2025年）框架協議項下之存款 服務年度上限的一項或多項適用百分比率高於0.1%但低於5%，故根據上市規則第14A 章，新金融服務（2025年）框架協議項下之 ...

Core Viewpoint - Southbound funds have reduced their holdings in China Traditional Chinese Medicine (00570.HK) by 3.266 million shares on November 13, with a total net reduction of 4 days amounting to 4.028 million shares over the last 5 trading days [1] Summary by Sections Southbound Fund Activity - In the last 20 trading days, southbound funds have reduced their holdings on 11 days, with a cumulative net reduction of 1.11 million shares [1] - As of now, southbound funds hold 1.583 billion shares of China Traditional Chinese Medicine, accounting for 31.42% of the company's total issued ordinary shares [1] Company Overview - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine [2] - The company operates through four divisions, focusing on the production and sales of traditional Chinese medicine formula granules, health products, and traditional Chinese medicine slices [2] - The Tianjiang division also provides healthcare solutions related to traditional Chinese medicine through offline medical institutions [2]

Core Insights - The report by Zhiyan Consulting highlights a significant decline in China's traditional Chinese medicine (TCM) material imports in September 2025, with a volume of 15,300 tons, representing a year-on-year decrease of 41.1% [1] - Conversely, TCM material exports in the same month reached 10,000 tons, showing a year-on-year increase of 16.4%, with export value amounting to 8 million USD, up by 12.9% [1] Import and Export Analysis - In September 2025, the import value of TCM materials was 2.4 million USD, reflecting a year-on-year decrease of 23.7% [1] - The data indicates a contrasting trend in exports, with a notable increase in both quantity and value, suggesting a potential growth opportunity in the international market for TCM [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年10月31日 | 狀態: 新提交 | | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | 公司名稱: | 中國中藥控股有限公司 | | | 呈交日期: | 2025年11月3日 | | | I. 法定/註冊股本變動 不適用 | | | FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00570 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 5,035,801,852 | | 0 | | 5,035,801,852 | | 增加 / 減少 (-) | | | | ...

Core Insights - The 22nd World Traditional Chinese Medicine Conference was held in Sydney, Australia, focusing on the theme of "Cultural Dissemination and Technological Innovation of Traditional Chinese Medicine (TCM) from a Global Perspective" [1][3] Group 1: Conference Overview - The conference was organized by the World Federation of Chinese Medicine Societies and supported by various Australian organizations, including the Australian Conference Bureau and the Australian Tourism Bureau [3] - Key participants included TCM experts, government officials, and business representatives from around the world, engaging in discussions on the international development of TCM [1][3] Group 2: Company Initiatives - Guangzhou Pharmaceutical Group, a major partner of the conference, showcased its latest achievements in TCM internationalization, technological innovation, and cultural dissemination [3] - The company’s chairman, Li Xiaojun, emphasized the importance of modernizing TCM through digital transformation and establishing a comprehensive international presence [3][6] Group 3: Strategic Collaborations - During the conference, Guangzhou Pharmaceutical Group signed multiple strategic cooperation agreements with various international entities, focusing on cultural promotion, research collaboration, and market expansion [8] - Notably, the Wanglaoji Health Company plans to launch the WALOVI international can in Australia, enhancing its overseas market presence [8] Group 4: Expert Contributions - The conference featured expert lectures, including a report on the regulation of TCM by Diane Wilkinson from the Australian government, providing policy guidance for TCM internationalization [6] - Other presentations included discussions on continuous innovation in TCM products, highlighting the collaborative efforts in research and development [6]

Core Insights - The report by Zhiyan Consulting highlights a significant decline in China's traditional Chinese medicine (TCM) material imports in August 2025, with a volume of 17,000 tons, representing a year-on-year decrease of 36.2% and an import value of 29 million USD, down 16.9% [1] - Conversely, TCM material exports in August 2025 reached 10,000 tons, showing a year-on-year increase of 2.4%, with an export value of 8.2 million USD, up 1.8% [1] Import Analysis - In August 2025, the import quantity of TCM materials was 17,000 tons, which is a significant drop of 36.2% compared to the previous year [1] - The import value for the same period was 29 million USD, reflecting a decrease of 16.9% year-on-year [1] Export Analysis - The export quantity of TCM materials in August 2025 was 10,000 tons, marking a growth of 2.4% compared to the previous year [1] - The export value during this period was 8.2 million USD, which is an increase of 1.8% year-on-year [1]

Group 1 - The core point of the news is that southbound funds have increased their holdings in China Traditional Chinese Medicine (00570.HK) significantly, with a total net increase of 14.23 million shares over the last five trading days and 40.55 million shares over the last twenty trading days [1][2] - As of October 22, 2025, southbound funds hold a total of 1.598 billion shares of China Traditional Chinese Medicine, representing 31.72% of the company's total issued ordinary shares [1][2] - The daily changes in shareholding show fluctuations, with a notable increase of 1.3292 million shares on October 21, 2025, and a decrease of 1.0828 million shares on October 17, 2025 [2] Group 2 - China Traditional Chinese Medicine Holdings Limited primarily engages in the manufacturing and sales of traditional Chinese medicine through four business segments [2] - The business segments include the production and sales of traditional Chinese medicine formula granules, health products, and decoction pieces, along with providing healthcare solutions through offline medical institutions [2]

Core Viewpoint - China National Pharmaceutical Group Corporation (Sinopharm Group) has announced the transfer of its 25% stake in China National Pharmaceutical Materials Co., Ltd. (Pharmaceutical Materials) to Shanghai Tianyue Tenghua Trading Service Co., Ltd. This transfer will be completed by September 30, 2025, and Sinopharm Group will no longer hold any equity in Pharmaceutical Materials [1][2]. Group 1 - After the completion of the stake transfer, China National Pharmaceutical Group and its subsidiary will have no equity or control relationship with Pharmaceutical Materials [1]. - Sinopharm Group has never authorized Pharmaceutical Materials to use its name, trademarks, or any intangible assets, and it does not take responsibility for any actions taken by Pharmaceutical Materials [1]. - The public and investors are advised to carefully verify the qualifications and creditworthiness of any entities they engage with, to assess cooperation risks and enhance risk prevention [1]. Group 2 - Pharmaceutical Materials has repeatedly used the name, trademarks, and rights of Sinopharm Group without authorization, constituting serious infringement, and legal proceedings have been initiated to hold them accountable [2]. - Sinopharm Group demands that Pharmaceutical Materials immediately cease any unauthorized use of its name, qualifications, and trademarks [2].

Core Viewpoint - China National Pharmaceutical Group announced the transfer of 25% equity in China National Medicine Co., Ltd. to Shanghai Tianyue Tenghua Trading Service Co., Ltd., resulting in no remaining equity or control relationship between the parties involved [1][2]. Summary by Sections Equity Transfer - The equity transfer will be completed by September 30, 2025, in the national property management information system, after which China National Medicine will no longer hold any shares in the pharmaceutical materials company [1][2]. Historical Context - China National Medicine was a founding shareholder of the pharmaceutical materials company, which may still be reflected in public records, leading to potential misinterpretations by the public and investors [2]. Unauthorized Use of Assets - The pharmaceutical materials company has repeatedly used the trademarks and intangible assets of China National Pharmaceutical Group without authorization, constituting serious infringement, and legal actions have been initiated to pursue accountability [3]. Legal Actions and Warnings - The company demands the immediate cessation of any unauthorized use of its trademarks and assets by the pharmaceutical materials company and warns of legal consequences for any impersonation or false association with China National Pharmaceutical Group [3].